Panbela Therapeutics, Inc. (PBLA) Misses Q2 EPS by $1.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PBLA Hot Sheet
Join SI Premium – FREE
Panbela Therapeutics, Inc. (NASDAQ: PBLA) reported Q2 EPS of ($1.51), $1.25 worse than the analyst estimate of ($0.26).
For earnings history and earnings-related data on Panbela Therapeutics, Inc. (PBLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c
- Cricut Inc. (CRCT) Tops Q3 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
